U.S. drugmaker Pfizer could work its connections within President Donald Trump's administration to try to thwart Novo Nordisk ...

Denmark's Novo Nordisk launched a rival bid for U.S. obesity biotech firm Metsera on Thursday, hijacking an offer from Pfizer ...

U.S. drugmaker Pfizer could work its connections within President Donald Trump's administration to try to thwart Novo Nordisk ...

Pfizer is suing over some unsolicited competition in its nearly $5 billion bid to buy the drugmaker Metsera. New York-based ...

The Wegovy and Ozempic maker’s offer comes after Pfizer last month agreed to a lower deal to acquire the Nasdaq-listed ...

Novo Nordisk and Pfizer are showing some desperation in their gloves-off tussle for the obesity-drug assets of Metsera.

A few years ago, Pfizer (NYSE: PFE) represented the ideal pharmaceutical stock investment. The company, as leader in the coronavirus vaccine and treatment market, offered a great deal of growth, and ...

The move, announced Thursday, escalates the competition between the two pharmaceutical giants for a critical advantage in the ...

The lawsuit escalates an unusual, high-profile battle between two large pharmaceutical companies over ownership of a coveted ...

The lawsuit says Novo Nordisk’s offer for drug startup Metsera isn’t reasonably likely to be completed.

Novo Nordisk ups its bid to acquire Metsera, intensifying the obesity drug market race and challenging Pfizer.

Novo Nordisk has submitted an unsolicited bid to buy obesity biotech Metsera out from under Pfizer, offering $6 billion ...